(Q35370321)

8 August 2017

1 reference

title

Chemotherapy of advanced transitional-cell carcinoma of the bladder (English)

1 reference

8 August 2017

1 reference

R. S. Miller

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1394829

22 September 2022

F. M. Torti

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1394829

22 September 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1394829

22 September 2022

publication date

1 January 1992

1 reference

Cancer Chemotherapy and Pharmacology

8 August 2017

1 reference

8 August 2017

30 Suppl

1 reference

8 August 2017

S99-110

1 reference

https://scigraph.springernature.com/pub.10.1007/bf00686953

8 August 2017

0 references

cites work

Chemotherapy of advanced transitional cell carcinoma of the uroepithelium

1 reference

12 December 2020

cis-Platinum combination chemotherapy of bladder cancer: an update

1 reference

12 December 2020

Methotrexate: an active drug in bladder cancer

1 reference

12 December 2020

Phase II study of etoposide for carcinoma of the bladder: the Southeastern Cancer Study Group experience

1 reference

12 December 2020

Phase II trial of sequentially administered cisplatin, cyclophosphamide and doxorubicin for urothelial tract tumors

1 reference

12 December 2020

Phase II trials with cis-dichlorodiammineplatinum(II) in the treatment of urothelial cancer

1 reference

12 December 2020

Systemic IFN-alpha treatment of multiple bladder papilloma grade I or II patients: pilot study

1 reference

12 December 2020

Chemotherapy for metastatic bladder cancer. Is there new hope?

1 reference

12 December 2020

A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma.

1 reference

12 December 2020

Chemotherapy of Bladder Carcinoma with Cyclophosphamide and Adriamycin

1 reference

12 December 2020

Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract

1 reference

12 December 2020

The management of advanced bladder carcinoma

1 reference

12 December 2020

Doxorubicin chemotherapy in advanced transitional cell carcinoma

1 reference

12 December 2020

Combination chemotherapy (CISCA) for advanced urinary tract carcinoma. A preliminary report

1 reference

12 December 2020

Chemotherapy of urothelial tract tumors

1 reference

12 December 2020

Single-drug chemotherapy with 5-FU and adriamycin in metastatic bladder cancer

1 reference

12 December 2020

Advanced transitional cell bladder cancer: a treatable disease

1 reference

12 December 2020

Oral VP-16-213 in transitional cell carcinoma of the bladder: a phase II study

1 reference

12 December 2020

Neoadjuvant chemotherapy for invasive bladder cancer

1 reference

12 December 2020

Cis-diamminedichloroplatinum (DDP) as initial treatment of invasive bladder cancer.

1 reference

12 December 2020

A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A National Bladder Cancer Collaborative Group A Study

1 reference

12 December 2020

Methotrexate and mitomycin for patients with metastatic transitional cell carcinoma of the urinary tract

1 reference

12 December 2020

Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study

1 reference

12 December 2020

Adriamycin and cyclophosphamide in advanced bladder cancer

1 reference

12 December 2020

Combination chemotherapy with cyclophosphamide, doxorubicin, and bleomycin for metastatic transitional cell carcinoma of the urinary tract

1 reference

12 December 2020

Cyclophosphamide, adriamycin and cisplatin combination chemotherapy in advanced bladder carcinoma: an EORTC phase II study

1 reference

12 December 2020

A phase II study of carboplatin in metastatic transitional cell carcinoma of the bladder (a report of the Medical Research Council Working Party on Urological Cancer, Subgroup in Advanced Bladder Cancer)

1 reference

12 December 2020

A phase 2 study of Cis-platinum in patients with recurrent bladder carcinoma. The London and Oxford Co-operative Urological Cancer Group

1 reference

12 December 2020

Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors

1 reference

12 December 2020

The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study

1 reference

12 December 2020

Treatment of genitourinary tumours with cis-dichlorodiammineplatinum(II): experience in 250 patients

1 reference

12 December 2020

Diamminedichloride platinum II and cyclophosphamide in the treatment of advanced urothelial cancer

1 reference

12 December 2020

The treatment of advanced bladder cancer with methotrexate and cis-platinum—a pharmacokinetic study

1 reference

12 December 2020

Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer

1 reference

12 December 2020

Phase II trial of cyclophosphamide, doxorubicin, and cisplatin (CAP) versus amsacrine in patients with transitional cell carcinoma of the urinary bladder: a Southwest Oncology Group study

1 reference

12 December 2020

Cancer statistics, 1992

1 reference

12 December 2020

Initial intravenous cis-platinum therapy: improved management for invasive high risk bladder cancer?

1 reference

12 December 2020

A phase II study of 4-epi-adriamycin in advanced urothelial transitional cell cancer. EORTC-GU Group protocol 30867.

1 reference

12 December 2020

Mitoxantrone in advanced bladder carcinoma. A phase II study of the EORTC Genito-urinary Tract Cancer Cooperative Group.

1 reference

12 December 2020

Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor

1 reference

12 December 2020

Cis-platin and methotrexate in the treatment of transitional cell carcinoma of the urinary tract

1 reference

12 December 2020

Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report

1 reference

12 December 2020

The treatment of advanced carcinoma of the bladder with a combination of adriamycin and 5-fluorouracil

1 reference

12 December 2020

Cis-diamminedichloroplatinum as a therapeutic agent in metastatic transitional cell carcinoma

1 reference

12 December 2020

Comparison of 5-FU and doxorubicin in the treatment of carcinoma of the bladder

1 reference

12 December 2020

The treatment of advanced carcinoma of the bladder with combination chemotherapy

1 reference

12 December 2020

Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial

1 reference

12 December 2020

Chemotherapy for metastatic transitional carcinoma of the urinary tract. A prospective trial of methotrexate, adriamycin, and cyclophosphamide (MAC) with cis-platinum for failure

1 reference

12 December 2020

Alpha-interferon in superficial bladder cancer: a Northern California Oncology Group Study

1 reference

12 December 2020

Chemotherapy in invasive carcinoma of the bladder. A review of phase II trials in Egypt

1 reference

12 December 2020

Phase II evaluation of adriamycin in human neoplasia

1 reference

12 December 2020

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

1 reference

12 December 2020

Dose response evaluation of adriamycin in human neoplasia

1 reference

12 December 2020

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience

1 reference

12 December 2020

Cis-dichlorodiammineplatinum(II) in advanced bladder cancer

1 reference

12 December 2020

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

12 December 2020

Combination chemotherapy with cisplatin and VM-26 in advanced transitional cell carcinoma of the bladder

1 reference

12 December 2020

Adriamycin in advanced urinary tract cancer.Experience in 42 patients and review of the literature

1 reference

12 December 2020

Treatment of advanced bladder cancer with adriamycin and 5-fluorouracil

1 reference

12 December 2020

Methotrexate as salvage or adjunctive therapy for primary invasive carcinoma of the bladder

1 reference

12 December 2020

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

1 reference

12 December 2020

Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer

1 reference

12 December 2020

Phase II study of 5-fluorouracil and adriamycin in transitional cell carcinoma of the urinary tract.

1 reference

12 December 2020

New combination chemotherapy programme for bladder cancer

1 reference

12 December 2020

Cyclophosphamide, doxorubicin, and cisplatin (CAP) in the treatment of urothelial malignancy: a pilot study of the Southeastern Cancer Study Group

1 reference

12 December 2020

Combination VM-26 and adriamycin for metastatic transitional cell carcinoma

1 reference

12 December 2020

A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract

1 reference

12 December 2020

Current perspectives in the management of high-grade invasive bladder cancer

1 reference

12 December 2020

Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B

1 reference

12 December 2020

Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium

1 reference

12 December 2020

Vincristine in advanced bladder cancer: a European organization for research on treatment of cancer (EORTC) phase II study

1 reference

12 December 2020

Biology and management of bladder cancer

1 reference

12 December 2020

Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium

1 reference

12 December 2020

Vinblastine and methotrexate for advanced bladder cancer.

1 reference

12 December 2020

Neoadjuvant chemotherapy for bladder cancer: the MSKCC experience

1 reference

12 December 2020

Overview of systemic treatment of bladder cancer and results with M-VAC therapy

1 reference

12 December 2020

Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer

1 reference

12 December 2020

Methotrexate in advanced bladder cancer

1 reference

12 December 2020

Adriamycin versus adriamycin plus cis-diamminedichloroplatinum (DDP) in advanced transitional cell bladder carcinoma. A Southwest Oncology Group study

1 reference

12 December 2020

Methotrexate, cisplatin and carboplatin as single agents and in combination for metastatic bladder cancer

1 reference

12 December 2020

Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00686953

1 reference

8 August 2017

1 reference